Not independent
Tenure on this board
5.0 yrs
Also a director at
Tarsus Pharmaceuticals Inc (TARS)Lensar Inc (LNSR)
Meeting calendar
RXST · Annual meeting · Tuesday, June 16, 2026
Rxsight Inc
3 nominees · 3 ballot items.
Elect three Class II directors; Advisory (non-binding) vote to approve named executive officer compensation (Say-on-Pay); Ratify Ernst & Young LLP as independent registered public accounting firm for 2026 fiscal year.
Market cap
$250M
1Y TSR
-40.1%
Board grade
C
Record date
Apr 21, 2026
Filing
DEF 14A
Meeting concluded · Jun 16, 2026
Follow how the vote landed and what changed on Rxsight Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect three Class II directors (William J. Link, Ph.D.; Robert Warner; Shweta Singh Maniar) to serve until the 2029 annual meeting.
- 2
Advisory Vote on Executive Compensation (Say-on-Pay
ManagementBoard: FORNon-binding advisory vote to approve the compensation of the named executive officers as disclosed in the proxy statement.
More detail
This proposal asks shareholders to cast a non-binding advisory vote to approve the company’s named executive officer compensation as disclosed in the proxy materials. Management seeks this advisory vote to gauge stockholder support for its pay practices and to demonstrate accountability in executive compensation decisions. The board recommends a vote FOR, stating the compensation program aligns pay with company performance, emphasizes long-term stockholder alignment through stock option grants, and uses market benchmarking and independent consultant advice. Context includes a 2025 compensation structure of base salary, annual bonus tied to corporate metrics (delighted customers, motivated employees, shareholder satisfaction), and long-term incentives delivered 100% as stock options with four-year vesting. The board notes prior strong stockholder support (87.1% in 2025) and commits to consider feedback if significant dissent occurs. Potential points of scrutiny include the size and form of equity awards (options vs. full-value grants), recent adjustments to salaries during 2025, and severance and change-in-control arrangements; however, management emphasizes risk controls (clawback policy, prohibition on hedging/pledging, independent compensation committee) and alignment with peers and retention needs.
- 3
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as RxSight’s independent registered public accounting firm for fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
5.0 yrs
Independent
Tenure on this board
4.6 yrs
Also a director at
Orthofix Medical Inc (OFIX)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | MILLENNIUM MANAGEMENT LLC | 5.0% | 2,059,459 | $13M |
| 2 | Artisan Partners Limited Partnership | 5.0% | 2,058,684 | $13M |
| 3 | NOMURA HOLDINGS INC | 4.8% | 2,000,060 | $12M |
| 4 | No Street GP LP | 4.8% | 2,000,000 | $12M |
| 5 | D. E. Shaw Co., Inc.Activist | 4.1% | 1,713,425 | $11M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 1,692,935 | $10M |
| 7 | BlackRock, Inc. | 3.2% | 1,328,818 | $8M |
| 8 | BlackRock, Inc. | 3.2% | 1,320,903 | $8M |
| 9 | TWO SIGMA INVESTMENTS, LP | 3.1% | 1,300,260 | $8M |
| 10 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2.7% | 1,131,400 | $7M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Rxsight Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Simulations Plus IncSLP
Special meeting·Aug 27, 2026·$371M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$740M
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.8B
Reference
Frequently asked questions
- When is the Rxsight Inc 2026 annual meeting?
- Rxsight Inc (RXST) holds its 2026 annual shareholder meeting on Tuesday, June 16, 2026.
- What is the record date for the Rxsight Inc 2026 meeting?
- The record date for the Rxsight Inc 2026 meeting is Tuesday, April 21, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Rxsight Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Rxsight Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Rxsight Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Rxsight Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.